The Chang Robotics Fund has invested in Suture Shield, a company that aims to enhance robotic surgery by utilizing patented technology to prevent needle loss, ultimately making surgical procedures safer and more efficient.

Target Information

Suture Shield is leading a transformative approach to robotic surgery that emphasizes enhanced safety, efficiency, and cost-effectiveness. A significant challenge faced during robotic-assisted surgeries is the phenomenon of needle loss, which occurs in approximately 3% of all procedures and can lead to an average delay of 35 minutes as resources are deployed to locate the lost needle. This not only contributes to increased healthcare costs but also heightens the risk of surgical complications.

To address this issue, Suture Shield has developed patented technology that effectively eliminates the risk of needle loss while also removing the need for an assistant, thereby saving around $750 per procedure. This innovation enables hospitals to decrease operational costs while simultaneously enhancing surgical precision and improving patient outcomes. The company's inception stems from the expertise of Dr. Steven Bowers, an accomplished robotic surgeon who recognized this critical challenge and dedicated his career to devising a solution. His experience culminated in the design and patenting of Suture Shield’s distinctive technology, which empowers surgeons to use their preferred needles without the risk of loss.

Industry Overview

The medical device sector, particularly in the realm of robotic surgery, is experiencing rapid advancements fueled by the increasing adoption of innovative technologies. The g